English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 27 April 2020, 17:26 JST
Share:
    

Source: Eisai
Eisai Selected as Most Honored Company and the First Place of the Sector in "The All-Japan Executive Team (Best IR Company Ranking)" by Institutional Investor Magazine

TOKYO, Apr 27, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been selected as "Most Honored Company" and has been ranked first place overall in the Biotechnology & Pharmaceuticals sector of "The All-Japan Executive Team", released by the US financial information magazine "Institutional Investor". This selection is based on Eisai's being ranked first place in "Best CEOs" and "Best CFOs", respectively, in the sector.


This survey is a ranking of the world-famous financial information magazine "Institutional Investor" that selects Japanese companies that perform outstanding IR activities by sector based on the votes of institutional investors and analysts around the world. In 2020, almost 350 investors and analysts from 189 securities firms and financial institutions voted. Eisai is highly praised for its high-quality IR activities such as investor conferences and proactive initiatives for ESG, while CEO Haruo Naito is highly praised for his credibility, quality of communication, and leadership.

For details, please refer to the "Institutional Investor" website: https://bit.ly/35gaVgo

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. In order to realize this philosophy, the Company will respect the rights of shareholders and investors, ensure fairness and transparency of management, and engage in IR activities that contribute to the enhancement of corporate value.

Topic: Press release summary
Source: Eisai

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Related News
Friday, 25 July 2025, 13:31 JST
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment
Wednesday, 23 July 2025, 10:07 JST
Launch of Beova(R) Tablets in Thailand for Overactive Bladder
Tuesday, 22 July 2025, 11:56 JST
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025
2025年7月16日 14時40分 JST
エーザイ、抗アミロイドβ抗体レカネマブの創薬研究が「第 9 回バイオインダストリー大賞」を受賞
Wednesday, 16 July 2025, 14:50 JST
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab
More news >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575